Abstract:Objectives: The objectives of the study were to investigate the responses of different retinal ganglion cell (RGC) populations to diverse injuries [transient ischemia induced by acute ocular hypertension (AOH), excitotoxicity induced by intravitreal injection of 100 mM N‐methyl D‐aspartate (NMDA) or intra‐orbital optic nerve transection (IONT)] and protection with selective agonists of the tropomyosin related kinase B (TrkB) receptor, brain‐derived neurotrophic factor (BDNF) or 7,8‐Dihydroxyflavone (DHF) or with a voltage‐dependent calcium channel blocker (ITH12657). Methods: Adult Sprague–Dawley rats were used. In the first group, the left eye received a single intravitreal injection of 5 μL vehicle or 5 μg BDNF and was connected to a saline reservoir elevated above the eye to induce an acute ocular hypertension (AOH) and transient ischemia for 75 min. These rats were analysed at different survival intervals from 3 to 45 days. A second group were treated daily subcutaneously with vehicle or ITH5263 (10 mg/kg), or intraperitoneally with vehicle or DHF (5 mg/kg), starting 12 h prior to an intraocular injection of 100 mM N‐methyl‐D‐aspartate (NMDA) to induce retinal excitotoxicity. These rats were analysed at different survival intervals from 3 to 21 days. A third group received a left intra‐orbital optic nerve transection (IONT) to induce axotomy of the RGC population and were treated daily with an intraperitoneal injection of vehicle (0.9% NaCl containing 1% DMSO) or DHF (5 mg/kg diluted in vehicle). These rats were analysed at survival intervals from 3 to 60 days. The retinas were prepared as wholemounts and immunolabelled for Brn3a, melanopsin (m), Osteopontin (OPN) and the T‐box transcription factor T‐brain‐2 (Tbr2) to identify the following retinal ganglion cell populations: Brn3a + , melanopsin + , α‐like (OPN + ), α‐ON sustained RGCs (OPN + Tbr2 + ), α‐ON transient RGCs (OPN + Brn3a − Tbr2 − ) and α‐OFF like (OPN + Brn3a + ). The labelled RGCs were quantified automatically (Brn3a) or dotted manually and quantified with a graphic software, and distribution of the different populations were represented on topographical maps. Results: Our studies document that: (i) AOH induces progressive loss of Brn3a + RGCs and a significant but not progressive loss of m + RGCs. Treatment with BDNF afforded significant long‐lasting protection for both RGC populations. (ii) Intravitreal injection of NMDA resulted at 7 days in the abrupt significant loss of Brn3a + RGCs, αRGC and αONs‐RGCs without further progression, whereas αOFF‐RGCs died massively. Both m + RGCs and αONtRGCs appear fully resistant to NMDA‐induced excitotoxicity. Both ITH12657 or DHF protect Brn3a + RGC, αRGCs and αONs‐RGCs, but not αOFF‐RGCs. (iii) IONT and vehicle treatment result in a characteristic rapid loss of Brn3a, melanopsin RGCs, αRGCs, αONs‐RGCs and αOFF‐RGCs. DHFs protect Brn3a + RGC, m + RGCs, αRGCs and αONs‐RGCs, but not αOFF‐RGCs. Conclusions: Thus, three different RGC populations (Brn3a + , m + and α‐like) respond distinctly to different injuries and neuroprotective agents, further adding to the idea that each type of RGC has a unique response to injury and protection. Deciphering the molecular mechanisms of each RGC type will help understand neuronal responses to injury and its possible prevention.

FK962 protects retinal ganglion cell under hypoxia/reoxygenation: Possible involvement of glial cell line-derived neurotrophic factor signaling pathway

A p75 neurotrophin receptor‐sparing nerve growth factor protects retinal ganglion cells from neurodegeneration by targeting microglia

Neuroprotective effects of a novel peptide, FK18, under oxygen-glucose deprivation in SH-SY5Y cells and retinal ischemia in rats via the Akt pathway

Germacrone Protects against NF-κB-Mediated Inflammatory Signaling, Apoptosis, and Retinal Ganglion Cell Survival in a Rat Glaucoma Model

Inhibition of the NR2B-PSD95 Interaction Exerts Neuroprotective Effects on Retinal Ischemia-Reperfusion Injury

Idiosyncratic responses of RGCs to injury and protection

GSK840 Alleviates Retinal Neuronal Injury by Inhibiting RIPK3/MLKL-Mediated RGC Necroptosis After Ischemia/Reperfusion

Keratin8 Deficiency Aggravates Retinal Ganglion Cell Damage under Acute Ocular Hypertension

Neuritin 1 Drives Therapeutic Preservation of Retinal Ganglion Cells in an Ex Vivo Human Glaucoma Model

Neuroprotection of Retinal Ganglion Cells in Glaucoma by Blocking Lingo-1 Function or Using A Nogo-66 Receptor Antagonist

Effects of Glial Cell Line-Derived Neurotrophic Factor on Cultured Murine Retinal Progenitor Cells

Neuroprotective Factors of the Retina and Their Role in Promoting Survival of Retinal Ganglion Cells: A Review

Sustained neurotrophic factor cotreatment enhances donor and host retinal ganglion cell survival in mice

COG1410 Regulates Microglial States and Protects Retinal Ganglion Cells in Retinal Ischemia-Reperfusion Injury.

Neuroprotective effect of gene transfection of cyclic adenosine monophosphate response element binding protein on primary murine retinal ganglion cells

Gastrodin protects retinal ganglion cells from ischemic injury by activating phosphatidylinositol 3-kinase/protein kinase B/nuclear factor erythroid 2-related factor 2 (PI3K/AKT/Nrf2) signaling pathway

Peroxisome Proliferator-Activated Receptor Α Activation Protects Retinal Ganglion Cells in Ischemia-Reperfusion Retinas.

Overexpression of S100A4 Protects Retinal Ganglion Cells Against Retinal Ischemia-Reperfusion Injury in Mice

TrkB Signaling in Retinal Glia Stimulates Neuroprotection after Optic Nerve Injury

Novel engineered, membrane-localized variants of vascular endothelial growth factor (VEGF) protect retinal ganglion cells: a proof-of-concept study

An Agonistic Trkb Mab Causes Sustained Trkb Activation, Delays Rgc Death, And Protects The Retinal Structure In Optic Nerve Axotomy And In Glaucoma